论文部分内容阅读
目的:对比观察α-硫辛酸联合单唾液酸四己糖神经节苷脂钠(GMI)治疗2型糖尿病性周围神经病变(DPN)的临床疗效及安全性。方法:选择并发周围神经病变的2型糖尿病94例,随机分为观察组和对照组各47例。两组均予控制血糖、血压、血脂等常规治疗,对照组在此基础上采用α-硫辛酸治疗,观察组采用α-硫辛酸联合GMI治疗。对比观察两组治疗前后临床症状和运动神经传导速度(MCV)、感觉神经传导速度(SCV)变化情况。结果:治疗3周后,观察组疼痛缓解、消失时间与麻木缓解、消失时间,均显著短于对照组(P<0.05);观察组的总有效率和显效率分别为93.6%、74.5%,均非常显著高于对照组的68.1%、25.5%(P<0.01);观察组治疗后MCV和SCV值均显著优于对照组(P<0.05);两组均未发生明显不良反应。结论:α-硫辛酸联合GMI治疗2型糖尿病性周围神经病变疗效显著,且安全性好,值得临床推广。
Objective: To compare the clinical efficacy and safety of α-lipoic acid combined with monosialotetrahexosyl ganglioside (GMI) in the treatment of type 2 diabetic peripheral neuropathy (DPN). Methods: A total of 94 type 2 diabetic patients with peripheral neuropathy were selected and randomly divided into observation group and control group with 47 cases each. Both groups were given conventional therapy such as blood sugar, blood pressure and blood lipids. The control group was treated with α-lipoic acid on the basis of the above. The observation group was treated with α-lipoic acid combined with GMI. The changes of clinical symptoms, motor nerve conduction velocity (MCV) and sensory nerve conduction velocity (SCV) were compared between the two groups before and after treatment. Results: After 3 weeks of treatment, pain relief, disappearance time and numbness relief and disappearance time in the observation group were significantly shorter than those in the control group (P <0.05). The total effective rate and markedly effective rate in the observation group were 93.6%, 74.5% (P <0.01). The MCV and SCV values in the observation group were significantly better than those in the control group (P <0.05). No significant adverse reactions occurred in both groups. Conclusion: Alpha-lipoic acid combined with GMI treatment of type 2 diabetic peripheral neuropathy significant effect, and the safety is good, worthy of clinical promotion.